CLAIMS

1. The use of acetaminophen in the manufacture of a medicament for reducing frequency of voluntary urination in a subject in need thereof, wherein said acetaminophen is administered at a daily dose of 1 mg to 2000 mg.

2. The use of Claim 1, wherein said medicament is formulated in a delayed-release formulation.

3. The use of Claim 2, wherein said delayed-release formulation comprises a material selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols, polyvinylpyrrolidone, methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and ethylcellulose.

4. The use of Claim 2, wherein said delayed-release formulation further comprises glyceryl monostearate or glyceryl distearate.

5. The use of Claim 2, wherein said delayed-release formulation comprises a water insoluble capsule body closed at one end with an insoluble, but permeable and swellable hydrogel plug, wherein said plug comprises a material selected from the group consisting of polymethacrylates, erodible compressed polymers, congealed melted polymer and enzymatically controlled erodible polymers.

6. The use of Claim 2, wherein said delayed-release formulation comprises an enteric coating.

7. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 50 mg to 500 mg.

8. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 500 mg to 2000 mg.

9. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 100 mg to 1500 mg.

10. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 250 mg to 1000 mg.

11. The use of Claim 1, wherein said medicament is formulated in an immediate-release formulation.

12. The use of Claim 1, wherein said medicament further comprises:

an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone,

wherein said analgesic agent is administered at a daily dose of 1 mg to 2000 mg.

13. The use of Claim 1, wherein said medicament further comprises one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

14. The use of Claim 1, wherein said medicament further comprises one or more antidiuretics.

15. The use of Claim 1, wherein said medicament further comprises one or more spasmolytics.

16. The use of Claim 1, further comprising:

administering to said subject a diuretic;

wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said medicament is administered within 2 hours prior to said target time.

17. The use of a pharmaceutical composition comprising a plurality of active ingredients, wherein said plurality of active ingredients comprise acetaminophen and one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine in the manufacture of a medicament for reducing frequency of voluntary urination in a subject in need thereof, and wherein said acetaminophen is administered at a daily dose of 50 mg to 2000 mg.

18. The use of Claim 17, wherein said medicament is formulated for immediate-release of said plurality of active ingredients.

19. The use of Claim 17, wherein said medicament is formulated for delayed-release of said plurality of active ingredients.

20. The use of Claim 17, wherein said plurality of active ingredients further comprises an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone.

21. The use of Claim 17, wherein said plurality of active ingredients further comprise one or more antidiuretics.

22. The use of Claim 17, wherein said plurality of active ingredients further comprise one or more spasmolytics.

23. A pharmaceutical composition, comprising:

acetaminophen;

one or more antidiuretics; and

a pharmaceutically acceptable carrier,

wherein said acetaminophen is formulated for delayed-release.

24. The pharmaceutical composition of Claim 23, further comprises one or more antimuscarinic agents.

25. The pharmaceutical composition of Claim 24, further comprises one or more spasmolytics.

CLAIMS

1. The use of acetaminophen in the manufacture of a medicament for reducing frequency of voluntary urination in a subject in need thereof, wherein said acetaminophen is administered at a daily dose of 1 mg to 2000 mg, and wherein said medicament further comprises one or more antidiuretics.

2. The use of Claim 1, wherein said medicament is formulated in a delayed-release formulation.

3. The use of Claim 2, wherein said delayed-release formulation comprises a material selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols, polyvinylpyrrolidone, methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and ethylcellulose.

4. The use of Claim 2, wherein said delayed-release formulation further comprises glyceryl monostearate or glyceryl distearate.

5. The use of Claim 2, wherein said delayed-release formulation comprises a water insoluble capsule body closed at one end with an insoluble, but permeable and swellable hydrogel plug, wherein said plug comprises a material selected from the group consisting of polymethacrylates, erodible compressed polymers, congealed melted polymer and enzymatically controlled erodible polymers.

6. The use of Claim 2, wherein said delayed-release formulation comprises an enteric coating.

7. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 50 mg to 500 mg.

8. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 500 mg to 2000 mg.

9. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 100 mg to 1500 mg.

10. The use of Claim 1, wherein said acetaminophen is administered at a daily dose of 250 mg to 1000 mg.

11. The use of Claim 1, wherein said medicament is formulated in an immediate-release formulation.

12. The use of Claim 1, wherein said medicament further comprises:
an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone.
wherein said analgesic agent is administered at a daily dose of 1 mg to 2000 mg.

13. The use of Claim 1, wherein said medicament further comprises one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

14. The use of Claim 1, wherein said medicament further comprises one or more spasmolytics.

15. The use of acetaminophen in the manufacture of a medicament for reducing frequency of voluntary urination in a subject in need thereof, wherein said acetaminophen is administered at a daily dose of 1 mg to 2000 mg, wherein said use further comprising:

administering to said subject a diuretic;

wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said medicament is administered within 2 hours prior to said target time.

16. The use of a pharmaceutical composition comprising a plurality of active ingredients,

wherein said plurality of active ingredients comprise acetaminophen and one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine in the manufacture of a medicament for reducing frequency of voluntary urination in a subject in need thereof,

wherein said acetaminophen is administered at a daily dose of 50 mg to 2000 mg, and

wherein said plurality of active ingredients further comprise one or more antidiuretics.

17. A pharmaceutical composition, comprising:

acetaminophen;

one or more antidiuretics; and

a pharmaceutically acceptable carrier,

wherein said acetaminophen is formulated for delayed-release.

18. The pharmaceutical composition of Claim 17, further comprises one or more antimuscarinic agents.

19. The pharmaceutical composition of Claim 18, further comprises one or more spasmolytics.